相关实验视频

Updated: Jun 15, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

针对局部高级NSCLC的响应适应疗法:整合ctDNA和放射学来实现风险分层

Valsamo Anagnostou^1,2, Charu Aggarwal^3,4,5

¹The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Cancer discovery

|August 4, 2025

概括

一个新的模型结合了治疗期间的ctDNA变化和成像特征,以预测局部晚期非小细胞肺癌患者的结果. 这种方法对实时量身定制化疗辐射疗法充满希望.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
分子诊断学分子诊断

背景情况:

局部晚期非小细胞肺癌 (NSCLC) 需要有效的风险分层来进行个性化治疗.
化学辐射是一种标准的治疗方法,但预测个体患者的反应仍然具有挑战性.
整合不同的数据源可以改善治疗决策.

研究的目的:

开发和验证一种多式风险分层模型,用于接受化学辐射治疗的局部晚期NSCLC患者.
评估结合循环瘤DNA (ctDNA) 动力学与放射性特征的实用性,以预测治疗结果.
探索实时响应适应性治疗在NSCLC中的潜力.

主要方法:

包括接受化学辐射治疗的局部晚期NSCLC患者.
分析了治疗中期的ctDNA水平和动力学.
从基线成像 (例如,CT扫描) 中提取放射性特征.
开发了一种整合ctDNA和放射性数据的多式模式,以预测治疗反应和结果.

主要成果:

新型多式联运模式证明了准确风险分层的概念验证.
与基线放射学相结合的ctDNA动力学与基线放射学相结合,与单个模式相比,提高了预测性能.
该模型显示了识别可能从适应性治疗策略中受益的患者的潜力.

结论:

结合ctDNA和放射性特征的多式风险分层模型对于局部先进的NSCLC是可行的和有前途的.
这种方法支持实时,响应适应化学辐射治疗的发展.
需要进一步的研究来标准化生物标志物并克服临床采用实施障碍.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...